PMID- 27582133
OWN - NLM
STAT- MEDLINE
DCOM- 20171128
LR  - 20240325
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 17
IP  - 1
DP  - 2016 Aug 31
TI  - Influence of high glucose and advanced glycation end-products (ages) levels in 
      human osteoblast-like cells gene expression.
PG  - 377
LID - 10.1186/s12891-016-1228-z [doi]
LID - 377
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with an increased risk 
      of osteoporotic fracture. Several factors have been identified as being 
      potentially responsible for this risk, such as alterations in bone remodelling 
      that may have been induced by changes in circulating glucose or/and by the 
      presence of non-oxidative end products of glycosylation (AGEs). The aim of this 
      study is to assess whether such variations generate a change in the gene 
      expression related to the differentiation and osteoblast activity (OPG, RANKL, 
      RUNX2, OSTERIX, and AGE receptor) in primary cultures of human osteoblast-like 
      cells (hOB). METHODS: We recruited 32 patients; 10 patients had osteoporotic hip 
      fractures (OP group), 12 patients had osteoporotic hip fractures with T2DM (T2DM 
      group), and 10 patients had hip osteoarthritis (OA group) with no osteoporotic 
      fractures and no T2DM. The gene expression was analyzed in hOB cultures treated 
      with physiological glucose concentration (4.5 mM) as control, high glucose 
      (25 mM), and high glucose plus AGEs (2 mug/ml) for 24 h. RESULTS: The hOB cultures 
      from patients with hip fractures presented slower proliferation. Additionally, 
      the hOB cultures from the T2DM group were the most negatively affected with 
      respect to RUNX2 and OSX gene expression when treated solely with high glucose or 
      with high glucose plus AGEs. Moreover, high levels of glucose induced a major 
      decrease in the RANKL/OPG ratio when comparing the OP and the T2DM groups to the 
      OA group. CONCLUSIONS: Our data indicates an altered bone remodelling rate in the 
      T2DM group, which may, at least partially, explain the reduced bone strength and 
      increased incidence of non-traumatic fractures in diabetic patients.
FAU - Miranda, Cristina
AU  - Miranda C
AD  - Bone Metabolism Unit, Internal Medicine Department, Virgen Macarena University 
      Hospital, Dr. Fedriani s/n, 41009, Seville, Spain.
FAU - Giner, Merce
AU  - Giner M
AD  - Bone Metabolism Unit, Internal Medicine Department, Virgen Macarena University 
      Hospital, Dr. Fedriani s/n, 41009, Seville, Spain.
AD  - Medicine Department, University of Seville, Dr. Fedriani s/n, 41009, Seville, 
      Spain.
FAU - Montoya, M Jose
AU  - Montoya MJ
AD  - Medicine Department, University of Seville, Dr. Fedriani s/n, 41009, Seville, 
      Spain. pmontoya@us.es.
FAU - Vazquez, M Angeles
AU  - Vazquez MA
AD  - Medicine Department, University of Seville, Dr. Fedriani s/n, 41009, Seville, 
      Spain.
FAU - Miranda, M Jose
AU  - Miranda MJ
AD  - Bone Metabolism Unit, Internal Medicine Department, Virgen Macarena University 
      Hospital, Dr. Fedriani s/n, 41009, Seville, Spain.
FAU - Perez-Cano, Ramon
AU  - Perez-Cano R
AD  - Bone Metabolism Unit, Internal Medicine Department, Virgen Macarena University 
      Hospital, Dr. Fedriani s/n, 41009, Seville, Spain.
AD  - Medicine Department, University of Seville, Dr. Fedriani s/n, 41009, Seville, 
      Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160831
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
RN  - 0 (Biomarkers)
RN  - 0 (Core Binding Factor Alpha 1 Subunit)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Osteoprotegerin)
RN  - 0 (RANK Ligand)
RN  - 0 (RUNX2 protein, human)
RN  - 0 (Sp7 Transcription Factor)
RN  - 0 (SP7 protein, human)
RN  - 0 (TNFSF11 protein, human)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/metabolism
MH  - *Bone Remodeling
MH  - Bone and Bones/*metabolism
MH  - Core Binding Factor Alpha 1 Subunit/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*metabolism/physiopathology
MH  - Female
MH  - Gene Expression
MH  - Glucose
MH  - Glycation End Products, Advanced
MH  - Hip Fractures/metabolism
MH  - Humans
MH  - Male
MH  - Osteoarthritis, Hip/metabolism
MH  - Osteoblasts/metabolism
MH  - Osteoporotic Fractures/*etiology/metabolism
MH  - Osteoprotegerin/metabolism
MH  - Primary Cell Culture
MH  - RANK Ligand/metabolism
MH  - Sp7 Transcription Factor/metabolism
PMC - PMC5007697
EDAT- 2016/09/02 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/08/31
CRDT- 2016/09/02 06:00
PHST- 2016/03/30 00:00 [received]
PHST- 2016/08/23 00:00 [accepted]
PHST- 2016/09/02 06:00 [entrez]
PHST- 2016/09/02 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/08/31 00:00 [pmc-release]
AID - 10.1186/s12891-016-1228-z [pii]
AID - 1228 [pii]
AID - 10.1186/s12891-016-1228-z [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2016 Aug 31;17(1):377. doi: 10.1186/s12891-016-1228-z.